文献速递药物相互作用

GSK3640254与代谢探针鸡尾酒在健康受试者中的开放标签药物相互作用研究

Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants.
PubMed 文献 · Br J Clin Pharmacol · 2023-03-13

本研究在健康受试者中评估HIV-1成熟抑制剂GSK3640254(GSK'254)对八种细胞色素P450和转运体探针底物药代动力学的影响。结果显示所有探针底物药代动力学参数的几何最小二乘均值比的90%置信区间提示无至弱相互作用,未发现新的安全性或耐受性问题。

要点

  • GSK'254 200 mg每日一次与八种CYP和转运体探针底物联用未显著改变底物药代动力学。
  • 所有探针底物PK参数的90%CI提示无至弱相互作用。
  • GSK'254稳态血浆浓度于第17天达到并维持至第21天。

核心结论

  • 健康受试者中GSK'254与代谢探针鸡尾酒联用对任何底物或相关代谢物PK的临床相关影响风险极低。
  • 未发现新的安全性或耐受性问题。
  • 结果支持GSK'254在HIV-1感染者中正在进行的IIb期和计划中的III期研究。

研究设计与样本

  • 开放标签药物相互作用研究。
  • 健康受试者第1天单次给予八种细胞色素P450和转运体探针底物鸡尾酒,洗脱10天后第11至20天每日一次GSK'254 200 mg,第21天单次给予鸡尾酒+GSK'254 200 mg。
  • 入组20例,19例完成研究。
  • 采用线性混合效应模型获得几何最小二乘均值比和90%置信区间。

主要发现

  • 所有鸡尾酒底物的血浆浓度在有或无GSK'254联用时总体相似。
  • 所有鸡尾酒底物PK参数的几何最小二乘均值比的90%CI提示无至弱相互作用。
  • GSK'254稳态血浆浓度于第17天达到并维持至第21天。
  • 9例参与者(45%)报告17例不良事件,其中大多数(88%)为1级。
  • 在单独给予GSK'254期间报告2例2级治疗相关不良事件(斑丘疹导致退出和丘疹)。

临床怎么用

  • GSK'254与CYP酶底物和转运体底物(包括其他抗逆转录病毒药)联用时预期无需调整剂量。

局限性

  • 研究在健康受试者中进行,未在HIV-1感染者中评估。
  • 开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: GSK3640254 (GSK'254) is an HIV-1 maturation inhibitor with pharmacokinetics (PK) supporting once-daily dosing. GSK'254 will be co-administered with cytochrome P450 enzyme substrates and drug transporters, including other antiretrovirals, in people living with HIV-1 (PLWH). METHODS: In this open-label study, healthy participants received a single dose of a cocktail of eight cytochrome P450 and transporter probe substrates on Day 1, followed by a 10-day washout before receiving GSK'254 200 mg once daily from Days 11 to 20 and a single dose of cocktail + GSK'254 200 mg on Day 21. Geometric least-squares mean ratios and 90% confidence intervals were obtained using linear mixed-effects models. Adverse events (AEs) were monitored. RESULTS: Of 20 participants enrolled, 19 completed the study. Plasma concentrations of all cocktail substrates were generally similar with or without GSK'254 co-administration. All 90% confidence intervals around geometric least-squares mean ratios for cocktail substrate PK parameters indicated no to weak interactions. Steady-state plasma GSK'254 concentrations were achieved by Day 17 and maintained through Day 21. Nine participants (45%) reported 17 AEs; most (88%) were grade 1. Two grade 2 treatment-related AEs (maculopapular rash [leading to withdrawal] and papular rash) were reported during GSK'254 administration alone. CONCLUSIONS: Co-administration of GSK'254 with a metabolic probe cocktail in healthy participants indicated very low risk of clinically relevant effect on PK of any substrates or associated metabolites. No new safety/tolerability concerns were identified. These results support ongoing phase IIb and planned phase III studies of GSK'254 in people living with HIV-1.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Johnson M, Joshi S, et al. Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. Br J Clin Pharmacol. 2023. PMID: 36822839. doi:10.1111/bcp.15699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。